Pharmaceutical marketers have more options than ever to reach healthcare providers. Channels have multiplied, from endemic media and programmatic display to EHR integrations. Data sources have expanded to include claims, scripts and modeled insights. Much of this activity, however, still depends on the same underlying NPI list-based approaches, some of which are still trying to serve both field forces and digital efforts at once. 

These lists, though, present consistent and contradictory issues to marketers: although lists are ubiquitous, they both over- and under-count relevant HCPs in some systematic ways, fundamentally because they have accounted only for retrospective signals and modeled assumptions. Historical prescribing, past diagnoses and propensity models describe what has already happened, but they offer limited insight into what clinicians are preparing to do next. In fast-moving clinical environments, this gap means brands miss or mishandle the critical windows before real prescription opportunities occur.  

Truly driving impact requires moving beyond static audience definitions and adopting engagement strategies that reach providers just before the prescribing moment. 
 

Why traditional provider engagement isn’t enough anymore


Traditional provider engagement models are designed to maximize reach and frequency. However, they struggle to deliver relevance during the increasingly narrow windows when clinical consideration can be influenced. 

Retrospective data reflects past behavior, not imminent decision making. A clinician who prescribed a medication months ago may not be encountering a similar patient again soon, or they may already be reassessing their treatment approach. Modeled audiences can extend scale, but they do so by prioritizing statistical likelihood over real-time readiness. This leads brands to reach more providers overall, while reaching fewer who are actively facing a relevant decision. The result is inefficiency and diluted message impact.

These limitations create a familiar disconnect. Providers receive messages that do not reflect their immediate priorities, and brands struggle to influence consideration during the brief time when decisions are taking shape. 

This disconnect is increasingly visible from the provider perspective. Visit times continue to shorten, with one study showing that the typical primary care provider would need 27 hours each day to give patients comprehensive care. Providers face increasing cognitive and operational pressure and are required to make decisions quickly. Messages that arrive late or lack relevance are easily tuned out. Influence is shaped less by volume and more by whether engagement aligns with the timing and context of clinical decision making.

According to research from IQVIA, 89% of healthcare providers report a preference for personalized interactions from pharmaceutical companies. Providers consistently value educational engagement that helps them stay current and address practical challenges, with the vast majority indicating it is important for brands to support them in navigating real-world clinical demands. When outreach lacks relevance or arrives outside of meaningful decision moments, it falls short of meeting the ultimate objective: helping providers care for their patients. 


The shift toward forward-looking provider engagement


Closing this gap requires a shift toward relevant and timely engagement, grounded in real clinical activity and upcoming decision opportunities.

Appointments are scheduled in advance and include significant information about the kinds of things an HCP may need to identify or discuss, as well as the decisions clinicians are likely to face. In primary care, routine visits are typically booked a couple of weeks out. Specialty care can involve extended wait times, with many OB/GYN, gastroenterology, dermatology and cardiology visits scheduled more than a month in advance. This advance visibility creates an influential engagement window before the patient interaction, when clinicians are preparing for upcoming conversations. The time immediately following a clinical interaction—while prior authorizations are being managed and other care actions are taken—represent additional opportunity for brands.

Phreesia Network Solutions has several years of experience supporting pharmaceutical marketers by helping brands reach patients as they prepare for meaningful health discussions. Now, with the introduction of ProviderConnect, Phreesia is extending its approach to providers, enabling engagement that reflects the clinical context that clinicians are actively navigating. 

ProviderConnect is not a replacement for existing strategies. It adds a new dimension—timing and context—that enhances the approaches brands already use. This approach improves performance while supporting clinicians in making confident decisions and helping patients move through care with less friction.

Thanks to advances in artificial intelligence, ProviderConnect surfaces scheduling signals drawn from real-world care, enabling brands to build audiences on factors such as upcoming appointments, visit types and active patient populations. These signals help brands engage providers when relevance is highest and decision preparation is underway, with the material that is best suited for that window of time. 

This elevates how provider marketing can be planned and executed. With ProviderConnect, messages arrive when they can support clinical preparation and prime an HCP to be on the look out for symptoms, side effects and other critical pieces of information in practice. By layering ProviderConnect insights into existing strategies, brands can increase relevance and efficiency and reduce waste without disrupting established workflows.


How forward-looking engagement benefits different brand needs


When timing becomes part of the engagement strategy, its impact extends across brand objectives. Consider these three very different circumstances and how the future view can improve delivery and lower waste:

  • Rare disease: Enabling earlier recognition and referral. Move beyond historical NPI interactions to upcoming consults where symptom patterns may signal diagnostic opportunity. Engagement can support earlier recognition, expert referral and treatment readiness at the moment it matters.
  • Switch strategies: Activating during likely therapy reassessment. Identify consults where category switches are more likely and equip clinicians with balanced information on side effects, coverage and alternatives, aligned to real decision windows. 
  • Launch treatments: Driving readiness around first eligible visits. Replace broad awareness with focused micro-bursts around initial eligible consults, coordinating media and field sequencing to build strong early confidence. 


Precision and readiness in provider engagement


The future of provider marketing centers on smarter engagements grounded in real-world care signals. Brands that adopt forward-looking approaches are better positioned to influence decisions as they are being made. 

Phreesia has spent more than two decades supporting pharmaceutical marketers activating patients based off clinical signals, and ProviderConnect represents a natural expansion of that expertise into provider marketing by applying the same high-quality signals to clinician engagement and activation.

To learn more about Phreesia’s ProviderConnect solution and how forward-looking engagement can strengthen your provider marketing strategy, request a demo today.